FDA
Approved Thursday via the FDA’s Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for hearing loss—and the first treatment to target an underlying cause of the condition.
FEATURED STORIES
BioSpace looks back at 2025 and where the FDA is going in 2026.
The FDA has gained a reputation during the past year for being inconsistently flexible, particularly when it comes to rare diseases. Executives at Rezolute and CERo Therapeutics recently had positive interactions with the agency, in which they told BioSpace reviewers have been “collaborative” and “curious.
Since the FDA began publishing its rejections of drug approval filings in July last year, companies have become more forthcoming about the details of agency decisions in their own disclosures, according to biopharma and regulatory analysts.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 28, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 25, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.
GlaxoSmithKline’s Trelegy Ellipta won regulatory approval for the treatment of asthma in patients aged 18 years and older. Here’s what you need to learn.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.